Bruker Corporation Total Assets
Bruker Corporation total assets. Based on the latest financial reports, Bruker Corporation (BRKR) holds total assets worth $6.24 Billion USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Bruker Corporation market cap and net worth for the company's overall valuation and market capitalisation.
Total Assets of Bruker Corporation (1998–2025)
Total assets of Bruker Corporation from 1998 to 2025. This chart illustrates how Bruker Corporation's total assets have evolved over time, based on quarterly financial data. See Bruker Corporation share price for real-time trading data and today's change.
Bruker Corporation - Asset Composition Analysis
Bruker Corporation Total Assets Breakdown (December 2025)
Bruker Corporation total assets breakdown as of December 2025. Bruker Corporation's total assets of $6.24 Billion consist of 35.5% current assets and 64.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 4.8% |
| Accounts Receivable | $736.00 Million | 11.8% |
| Inventory | $1.09 Billion | 17.5% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $899.60 Million | 14.4% |
| Goodwill | $1.55 Billion | 24.8% |
Asset Composition Trend (1998–2025)
This chart illustrates how Bruker Corporation's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Bruker Corporation (BRKR) liquidity to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Bruker Corporation's current assets represent 35.5% of total assets in 2025, an increase from 0.0% in 1998.
- Cash Position: Cash and equivalents constituted 4.8% of total assets in 2025, up from 0.0% in 1998.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 38.0% of total assets, an increase from 0.0% in 1998.
- Asset Diversification: The largest asset category is goodwill at 24.8% of total assets.
Bruker Corporation Competitors by Total Assets
Key competitors of Bruker Corporation based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shenzhen New Industries Biomedical
SHE:300832
|
China | CN¥9.58 Billion |
|
GN Store Nord
CO:GN
|
Denmark | Dkr29.23 Billion |
|
Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A
SHG:688212
|
China | CN¥1.86 Billion |
|
Polynovo Ltd
AU:PNV
|
Australia | AU$123.37 Million |
|
L&C Bio Co. Ltd
KQ:290650
|
Korea | ₩497.94 Billion |
|
VIROMED MEDICAL NA O.N.
XETRA:VME
|
Germany | €13.91 Million |
|
Affluent Medical SAS
PA:AFME
|
France | €59.84 Million |
|
DRGEM Corporation
KQ:263690
|
Korea | ₩131.65 Billion |
Bruker Corporation - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.73 | 1.60 | 2.06 |
| Quick Ratio | 0.87 | 0.77 | 1.32 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $933.30 Million | $771.90 Million | $1.00 Billion |
Bruker Corporation - Advanced Valuation Insights
This section examines the relationship between Bruker Corporation's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.28 |
| Latest Market Cap to Assets Ratio | 0.93 |
| Asset Growth Rate (YoY) | 7.5% |
| Total Assets | $6.24 Billion |
| Market Capitalization | $5.82 Billion USD |
Valuation Analysis
Near Book Valuation: The market values Bruker Corporation's assets close to their book value (0.93x), suggesting investors view the company's assets at approximately fair value.
Positive Asset Growth: Bruker Corporation's assets grew by 7.5% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Bruker Corporation (1998–2025)
The table below shows the annual total assets of Bruker Corporation from 1998 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $6.24 Billion | +7.49% |
| 2024-12-31 | $5.81 Billion | +36.63% |
| 2023-12-31 | $4.25 Billion | +17.67% |
| 2022-12-31 | $3.61 Billion | -1.05% |
| 2021-12-31 | $3.65 Billion | +19.71% |
| 2020-12-31 | $3.05 Billion | +10.01% |
| 2019-12-31 | $2.77 Billion | +30.20% |
| 2018-12-31 | $2.13 Billion | +9.24% |
| 2017-12-31 | $1.95 Billion | +7.48% |
| 2016-12-31 | $1.81 Billion | +4.74% |
| 2015-12-31 | $1.73 Billion | -7.18% |
| 2014-12-31 | $1.86 Billion | -6.21% |
| 2013-12-31 | $1.99 Billion | +7.11% |
| 2012-12-31 | $1.86 Billion | +8.53% |
| 2011-12-31 | $1.71 Billion | +10.37% |
| 2010-12-31 | $1.55 Billion | +32.24% |
| 2009-12-31 | $1.17 Billion | +4.99% |
| 2008-12-31 | $1.12 Billion | +101.78% |
| 2007-12-31 | $553.21 Million | +27.71% |
| 2006-12-31 | $433.19 Million | +20.03% |
| 2005-12-31 | $360.89 Million | -2.87% |
| 2004-12-31 | $371.55 Million | +5.84% |
| 2003-12-31 | $351.03 Million | +72.83% |
| 2002-12-31 | $203.10 Million | +7.42% |
| 2001-12-31 | $189.07 Million | +2.45% |
| 2000-12-31 | $184.55 Million | +174.19% |
| 1999-12-31 | $67.31 Million | +5.43% |
| 1998-12-31 | $63.84 Million | -- |
About Bruker Corporation
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions. It operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. The company offers magnetic resonance spectroscop, preclinical imaging, biopharma and applied, ser… Read more